[go: up one dir, main page]

PE20090154A1 - Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13 - Google Patents

Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13

Info

Publication number
PE20090154A1
PE20090154A1 PE2008000699A PE2008000699A PE20090154A1 PE 20090154 A1 PE20090154 A1 PE 20090154A1 PE 2008000699 A PE2008000699 A PE 2008000699A PE 2008000699 A PE2008000699 A PE 2008000699A PE 20090154 A1 PE20090154 A1 PE 20090154A1
Authority
PE
Peru
Prior art keywords
variable domain
less
amino acid
refers
acid substitutions
Prior art date
Application number
PE2008000699A
Other languages
English (en)
Inventor
Yulia Vugmeyster
Xin Xu
Xianbin Tian
Donald G Raible
Yuji Simon Zhou
Billie Durn
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20090154A1 publication Critical patent/PE20090154A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)

Abstract

SE REFIERE A UN METODO PARA EVALUAR UNA MOLECULA DE ANTICUERPO ANTI-IL-13, QUE COMPRENDE EN PROPORCIONAR UN VALOR DE ENSAYO MEDIO PARA AL MENOS UN PARAMETRO PK/PD DE UNA MOLECULA DE ANTICUERPO ANTI-IL-13 EN UN SUJETO Y COMPARAR EL VALOR DEL ENSAYO MEDIO CON AL MENOS UN VALOR DE REFERENCIA MEDIO, SELECCIONADO DE UN RANGO APROXIMADO DE 0,05 A 0,9 ml/hr/kg, Vdss 150ml/kg, T1/2 DE 500-800 HORAS, UNA CONCENTRACION MAXIMA MEDIA NORMALIZADA DE 2 A 40 ug/ml; BIODISPONIBILIDAD DE 60-90% Y UN CLEARANCE MEDIO DE MENOS DE 0,004 ml/hr/kg CUANDO SE FORME EL COMPLEJO CON IL-13. DICHA MOLECULA DE ANTICUERPO TIENE ALGUNAS DE LAS SIGUIENTES PROPIEDADES: a)UN DOMINIO VARIABLE DE CADENA PESADA QUE COMPRENDE UNA CDR3 QUE DIFIERE EN MENOS DE 3 SUSTITUCIONES DE AMINOACIDO; b)UN DOMINIO VARIABLE DE CADENA LIGERA QUE COMPRENDE UNA CDR QUE DIFIERE EN MENOS DE 3 SUSTITUCIONES DE AMINOACIDO; c)UNA SECUENCIA DE DOMINIO VARIABLE DE INMUNOGLOBULINA AL MENOS 90% INDENTICA A V2.1, V2.3, V2.4, ENTRE OTROS. SE REFIERE TAMBIEN A UN ESQUEMA DE DOSIS
PE2008000699A 2007-04-23 2008-04-23 Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13 PE20090154A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92593207P 2007-04-23 2007-04-23
US92607807P 2007-04-23 2007-04-23

Publications (1)

Publication Number Publication Date
PE20090154A1 true PE20090154A1 (es) 2009-03-31

Family

ID=39689094

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000699A PE20090154A1 (es) 2007-04-23 2008-04-23 Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13

Country Status (14)

Country Link
US (1) US20090068195A1 (es)
EP (1) EP2137215A2 (es)
JP (1) JP2010527916A (es)
CN (1) CN101977935A (es)
AR (1) AR066240A1 (es)
BR (1) BRPI0810561A2 (es)
CA (1) CA2685123A1 (es)
CL (1) CL2008001182A1 (es)
MX (1) MX2009011366A (es)
PA (1) PA8778101A1 (es)
PE (1) PE20090154A1 (es)
RU (1) RU2009140134A (es)
TW (1) TW200848429A (es)
WO (1) WO2008131376A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0509512D0 (en) * 2005-05-10 2005-06-15 Novartis Ag Organic compounds
CN102076355B (zh) * 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
AU2009256246B2 (en) * 2008-06-03 2013-07-18 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009268585C1 (en) * 2008-07-08 2014-10-02 Abbvie Inc. Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
GB0905972D0 (en) 2009-04-06 2009-05-20 Medical Res Council Antibodies against IL-17BR
TW201109438A (en) * 2009-07-29 2011-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
TW201119673A (en) * 2009-09-01 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2011043538A2 (ko) * 2009-10-08 2011-04-14 주식회사이언메딕스 실내 공기유래 세포밖 소포체를 포함하는 조성물 및 이의 용도
UY32948A (es) * 2009-10-15 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103260639A (zh) 2010-08-26 2013-08-21 Abbvie公司 双重可变结构域免疫球蛋白及其用途
MX2013004979A (es) * 2010-11-02 2013-07-30 Abbott Lab Inmunoglobulinas de dominio variable doble y usos de las mismas.
EP3461847B1 (en) 2010-12-06 2020-09-23 Seattle Genetics, Inc. Humanized antibodies to liv-1 and use of same to treat cancer
KR101615474B1 (ko) 2010-12-16 2016-04-25 제넨테크, 인크. Th2 억제에 관한 진단 및 치료
CN109734807A (zh) * 2011-03-31 2019-05-10 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
HK1198328A1 (zh) * 2011-07-13 2015-04-02 Abbvie Inc. 使用抗il-13抗體治療哮喘的方法和組合物
WO2013102042A2 (en) 2011-12-30 2013-07-04 Abbvie Inc. Dual specific binding proteins directed against il-13 and/or il-17
MX370486B (es) * 2012-03-27 2019-12-16 Genentech Inc Composiciones, métodos y usos para asistir en el diagnóstico, pronóstico y tratamiento de la fibrosis pulmonar idiopática.
KR20150021088A (ko) * 2012-06-05 2015-02-27 디 오스트레일리언 내셔널 유니버시티 인터루킨-4 길항제를 이용한 백신접종
HK1212359A1 (en) 2012-11-01 2016-06-10 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
JP6898303B2 (ja) 2015-08-07 2021-07-07 エーエルエックス オンコロジー インコーポレイテッド Ｓｉｒｐ−アルファドメインまたはそのバリアントを有する構築物
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN109705217B (zh) * 2017-10-25 2020-09-11 北京智仁美博生物科技有限公司 抗il-13抗体及其用途
MA53493A (fr) * 2018-08-31 2021-07-07 Alx Oncology Inc Polypeptides leurres
EP3947457A1 (en) * 2019-03-26 2022-02-09 ASLAN Pharmaceuticals Pte Ltd Treatment employing anti-il-13r antibody or binding fragment thereof
US11613564B2 (en) 2019-05-31 2023-03-28 ALX Oncology Inc. Methods of treating cancer
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
CN118255891B (zh) * 2024-03-14 2025-03-11 北京赛斯维德生物科技有限公司 检测尿液11-脱氢血栓烷b2/肌酐的试剂盒及检测方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) * 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5359037A (en) * 1988-09-12 1994-10-25 Yeda Research And Development Co. Ltd. Antibodies to TNF binding protein I
WO1990005183A1 (en) * 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5246701A (en) * 1990-10-05 1993-09-21 Ludwig Institute For Cancer Research Method for inhibiting production of IgE by using IL-9 inhibitors
ATE130869T1 (de) * 1991-03-29 1995-12-15 Sanofi Sa Protein mit der aktivität vom typ von cytokin, dafür kodierende rekombinante dns, transformierte zellen und mikroorganismen.
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
EP0721346B1 (en) * 1993-09-02 1998-06-10 Trustees of Dartmouth College Methods for inducing antigen-specific t cell tolerance
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
GB9415379D0 (en) * 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5696234A (en) * 1994-08-01 1997-12-09 Schering Corporation Muteins of mammalian cytokine interleukin-13
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6911530B1 (en) * 1995-10-23 2005-06-28 Amrad Operations, Pty., Ltd. Haemopoietin receptor and genetic sequences encoding same
FR2742156A1 (fr) * 1995-12-06 1997-06-13 Sanofi Sa Polypeptide recepteur de l'il-13
US7078494B1 (en) * 1996-03-01 2006-07-18 Genetics Institute, Llc Antibodies to human IL-13bc and methods of their use in inhibiting IL-13 binding
US5710023A (en) * 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
US6664227B1 (en) * 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6387615B2 (en) * 1997-04-11 2002-05-14 Isis Innovation Limited Methods and materials for the diagnosis or prognosis of asthma
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
JP4460155B2 (ja) * 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
US6746839B1 (en) * 1998-01-12 2004-06-08 Interleukin Genetics, Inc. Diagnostics and therapeutics for an obstructive airway disease
US6576232B1 (en) * 1998-04-03 2003-06-10 The Penn State Research Foundation IL13 mutants
US7083950B2 (en) * 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
ES2277460T3 (es) * 1998-12-14 2007-07-01 Genetics Institute, Llc Cadena del receptor de la citoquina.
US7553487B2 (en) * 1998-12-14 2009-06-30 Genetics Institute, Llc Method and compositions for treating asthma
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB0004016D0 (en) * 2000-02-22 2000-04-12 Royal Brompton Hospital Biological material and uses thereof
EP1268794A2 (en) * 2000-04-07 2003-01-02 Heska Corporation Compositions and methods related to canine igg and canine il-13 receptors
AU8867501A (en) * 2000-09-01 2002-03-13 Biogen Inc Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
AUPR544401A0 (en) * 2001-06-04 2001-06-28 Bischof, Robert Juergen Animal model for allergy
EP1402451A4 (en) * 2001-06-07 2005-01-05 Wyeth Corp SOLUTION STRUCTURE OF IL-13 AND USE THEREOF
US7321026B2 (en) * 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
US20040248260A1 (en) * 2001-10-26 2004-12-09 Heavner George A. IL-13 mutein proteins, antibodies, compositions, methods and uses
US20040234499A1 (en) * 2001-10-26 2004-11-25 David Shealy Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
CA2468950A1 (en) * 2001-11-27 2003-06-05 Mochida Pharmaceutical Co., Ltd. Anti-il13 receptor .alpha.1 neutralizing antibody
CA2469082A1 (en) * 2001-12-04 2003-06-12 Raj K. Puri Chimeric molecule for the treatment of th2-like cytokine mediated disorders
WO2003080675A2 (en) * 2002-03-22 2003-10-02 Amrad Operations Pty Ltd MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1)
AU2003223497A1 (en) * 2002-04-05 2003-10-27 Centocor, Inc. Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
CA2480777A1 (en) * 2002-05-01 2003-11-13 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat hiv infection and aids
JP4689268B2 (ja) * 2002-06-14 2011-05-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１３およびｎｋ−ｔ細胞に関する、結腸炎を処置および予防する方法
JP2004121218A (ja) * 2002-08-06 2004-04-22 Jenokkusu Soyaku Kenkyusho:Kk 気管支喘息または慢性閉塞性肺疾患の検査方法
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
PL1711528T3 (pl) * 2003-12-23 2012-11-30 Genentech Inc Leczenie nowotworu nowymi przeciwciałami monoklonalnymi anty-IL13
WO2005062918A2 (en) * 2003-12-24 2005-07-14 Wyeth Methods of treating asthma
EP1713441A2 (en) * 2004-02-12 2006-10-25 Nektar Therapeutics Interleukin-13 antagonist powders, spray-dried particles, and methods
US20050266005A1 (en) * 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
US20090098142A1 (en) * 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
US20070048785A1 (en) * 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
BRPI0720280A2 (pt) * 2006-12-11 2014-01-28 Wyeth Corp Métodos e composições para tratar e monitorar tratamento de desordens associadas à il-13

Also Published As

Publication number Publication date
CN101977935A (zh) 2011-02-16
EP2137215A2 (en) 2009-12-30
JP2010527916A (ja) 2010-08-19
WO2008131376A2 (en) 2008-10-30
BRPI0810561A2 (pt) 2019-09-24
AR066240A1 (es) 2009-08-05
CA2685123A1 (en) 2008-10-30
CL2008001182A1 (es) 2009-01-16
US20090068195A1 (en) 2009-03-12
TW200848429A (en) 2008-12-16
MX2009011366A (es) 2009-11-05
RU2009140134A (ru) 2011-05-27
PA8778101A1 (es) 2008-11-19
WO2008131376A3 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
PE20090154A1 (es) Metodos para tratar y monitorear el tratamiento de transtornos asociados con il-13
CY1111927T1 (el) Νεες ενωσεις ως διαμορφωτες υποδοχεα οπιοειδων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1113386T1 (el) Αναστολεις πρωτεασωματος
CY1125152T1 (el) Συνθεσεις και μεθοδοι για τη μειωση της νεοαγγειωσης του οφθαλμου
CY1121882T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1119576T1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
CY1122366T1 (el) Θεραπεια της οξειας λεμφοβλαστικης λευχαιμιας
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
CY1119711T1 (el) Νεα ενωση χρησιμη για τη θεραπεια εκφυλιστικων και φλεγμονωδων ασθενειων
NO20072035L (no) Memantin for behandling av adferdsforstyrrelser hos barn
HRP20050826B1 (hr) Ciklički inhibitori proteinske tirozin kinaze
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
CY1121538T1 (el) Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi)
CY1109104T1 (el) 1,2,3,4 τετρα-υποκατεστημενη ινδολη για την αντιμετωπιση ασθενειων του αναπνευστικου
CY1111197T1 (el) Tριαζολες χρησιμες ως αναστολεις πρετεϊνικων κινασων
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
EA201591402A1 (ru) Спиролактамные модуляторы nmda-рецептора и их применение
CY1118966T1 (el) Νεες συνθεσεις για την προληψη και/ή την θεραπεια εκφυλιστικων διαταραχων του κεντρικου νευρικου συστηματος
JOP20220030A1 (ar) صيغ مضادة لـ c5 عالية التركيز
CY1110190T1 (el) Παραγωγα πιπεραζινυλιου χρησιμα στην αγωγη των νοσων στις οποιες μεσολαβει ο υποδοχεας gpr38
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου

Legal Events

Date Code Title Description
FX Voluntary withdrawal